The use of a 4.7 mg deslorelin slow release implant in male dogs in the field.

OBJECTIVE: Slow-release GnRH agonist implants (SRI) are used for reversible medical downregulation of testicular function in male dogs as an alternative to surgery. The 4.7 mg deslorelin SRI should reduce testosterone after 6-8 weeks and induce castration-like effects for 6 months (mon). However, some individual variation is described in the field in regard to onset and duration of effect. For this reason, we aimed to study the effects of the 4.7 mg deslorelin SRI in a larger cohort. MATERIAL AND METHODS: In total 50 intact, healthy male dogs (12-48 months, mon; 9-40 kg) were treated with a 4.7 mg deslorelin SRI into the umbilical area (TG, n=45) or served as untreated controls (CG, n=5). CG dogs were surgically castrated after measurement of testicular dimensions and blood sampling for testosterone. In TG, SRIs remained for 5 mon in place and subsequently 3-7 male dogs were surgically castrated at removal (week, W 0) or 1, 2, 3, 4, 5, 6, 7, 8 or 10 weeks later. Examination parameters were testicular dimensions (before treatment, at 4, 8, 12 W, 5 mon, weekly until castration), testosterone (before treatment, at 8 W, 5 mon, castration) and testicular histology (castration). RESULTS: Whereas examination parameters did not differ between CG and TG before treatment, testicular volume and testosterone was significantly reduced at all time points during treatment. In all but 3 (8 W) and 2 male dogs (5 mon) testosterone was basal during treatment before removal, whereas the parameters were significantly reduced compared to pre-treatment in the respective dogs. After implant removal, testosterone and testicular volumes increased. However, different to earlier studies, the "restart" was more variable with individual basal testosterone until W7, but also physiological testosterone concentrations in W2. Similarly, histological testicular findings at castration were quite variable: besides an arrest on spermatogonia and spermatocytes, elongated spermatids with normal spermatogenesis were found in individual dogs. CONCLUSION: Our study confirms the efficacy of the deslorelin SRI, but also individual variation especially regarding reversibility of effects on endocrine and germinative testicular function. CLINICAL RELEVANCE: Deslorelin SRIs offer a suitable alternative to surgical castration with individual variation to be considered when used in clinical practice.

Evaluation of sperm counting accuracy on computer-assisted sperm analysis with GoldCyto® slides and glass slides.

Worldwide, various counting chambers and computer-assisted sperm analysis (CASA) devices are in use. The semen's concentration can vary depending on the depth of the counting chamber and how it is loaded. The study's objectives were to analyze the effects of various counting chambers on semen concentration results using a GoldCyto® slide and a glass slide in the CASA system and to ascertain the precision of concentration measurements made using glass slides on CASA. The study's control group was composed of samples with known concentrations (72-80 million sperm/mL) as determined by a spectrophotometer. A total of 21 frozen straws from the same bull of the same date were thawed at 37°C for 30 s and loaded into two different sperm-counting chambers (GoldCyto® slide and glass slide). The sample semen placed in the sperm counting chambers was 5 µL and the same value was entered in the CASA software as 5 µL. Measurements were done and evaluated in 5 different areas. According to the data we obtained, using the glass slide were statistically lower than the spectrophotometer (p < 0.001). GoldCyto® slide results were consistent with spectrophotometer results. Consequently, measurements with GoldCyto® slides in the CASA had consistent results, while measurements with glass slides were inconsistent. It was concluded that GoldCyto® slides are more suitable than glass slides in the concentration examinations of semen. Therefore, more study is needed to optimize the use of glass slides.